"It’s a privilege to work with visionary entrepreneurs who are creating the technologies and procedures that define the future of medical care. And it’s exciting to help them craft business strategies that propel and transform their ideas into market penetration and real-world success."
As a successful digital health investor, Gil built this important franchise for InterWest over the last twenty years through multiple companies. He led the Series A of Epocrates, the industry-leading first mobile application for physicians, serving on the board through its 2011 IPO, and was the founding institutional investor in Doximity, helping to build it into the leading physician social network engaging over 70% of U.S. physicians with over one million total users.
Gil serves on the board of Orbis International, a global not-for-profit organization focused on preventing blindness. He is also a Co-Founder and Program Director of Ophthovation, an ophthalmology innovation conference supported by a joint venture of the American Academy of Ophthalmology and the American Society of Cataract and Refractive Surgery. Previously, he helped to launch the Ophthalmology Innovation Summit (OIS), an ophthalmology business conference that he co-chaired from 2010 to 2018.
A former practicing ophthalmologist, Gil completed an ophthalmology residency at Wills Eye Hospital and a retina fellowship at Massachusetts Eye and Ear Infirmary as a Heed Foundation fellow. He has a BA from Harvard University, an MD from the University of Pennsylvania and an MBA from Stanford University.
Representative Prior Investments
Over the last 20 years I have had the privilege of diverse life experiences as a laser researcher, practicing physician, startup company founder, and technology venture capitalist. I most enjoy being on the front edge of new technology waves, looking over the horizon for non-obvious opportunities... What I find exciting is working alongside visionary entrepreneurs, thinking non-traditionally, and helping to identify creative strategies to make pioneering ventures even more successful.